脑转移瘤影像组学特征:预测EGFR突变状态
回顾性分析52例肺腺癌脑转移患者(28例EGFR突变、24例野生型),从T1-CE、T2-FLAIR、T2WI和DWI提取影像组学特征。基于T2-FLAIR的9个特征构建的影像组学标签在验证队列中AUC为0.987、准确率0.991、敏感度1.000、特异度0.980,独立测试集AUC为0.871。
要点
- T2-FLAIR序列的影像组学标签对预测肺腺癌脑转移EGFR突变状态表现出良好鉴别能力。
- 验证队列中T2-FLAIR标签AUC 0.987、准确率0.991、敏感度1.000、特异度0.980。
- 独立测试集AUC为0.871,区分外显子19与外显子21突变的AUC均较低。
核心结论
- 基于T2-FLAIR的影像组学标签可作为无创辅助工具预测肺腺癌脑转移的EGFR突变状态,有助于指导治疗策略。
研究设计与样本
- 回顾性分析52例肺腺癌脑转移患者,其中EGFR突变28例、野生型24例。
- 从T1-CE、T2-FLAIR、T2WI和DWI序列各提取438个影像组学特征。
- 各序列随机分为训练队列和验证队列,采用最小绝对收缩选择算子筛选特征,以训练队列的逻辑回归模型构建影像组学标签。
- 使用验证队列和独立测试数据集评估影像组学标签性能。
关键影像表现/征象
- 基于T2-FLAIR的9个所选特征构建的影像组学标签在训练队列和验证队列中均表现出良好鉴别能力。
诊断标准与关键数值
- T2-FLAIR影像组学标签在验证队列中AUC为0.987、分类准确率为0.991、敏感度为1.000、特异度为0.980。
- T2-FLAIR影像组学标签在独立测试数据集中的AUC为0.871。
- 区分外显子19与外显子21突变的AUC:T1-CE为0.529、T2-FLAIR为0.580、T2WI为0.645、DWI为0.406。
临床应用与阅片要点
- 作者认为基于T2-FLAIR的影像组学标签可作为无创辅助工具预测肺腺癌脑转移EGFR突变状态,有助于指导治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To predict epidermal growth factor receptor (EGFR) mutation status in lung adenocarcinoma using MR-based radiomics signature of brain metastasis and explore the optimal MR sequence for prediction.
METHODS: Data from 52 patients with brain metastasis from lung adenocarcinoma (28 with mutant EGFR, 24 with wild-type EGFR) were retrospectively reviewed. Contrast-enhanced T1-weighted imaging (T1-CE), T2 fluid-attenuated inversion recovery (T2-FLAIR), T2WI, and DWI sequences were selected for radiomics features extraction. A total of 438 radiomics features were extracted from each MR sequence. All sequences were randomly divided into training and validation cohorts. The least absolute shrinkage selection operator was used to select informative features, a radiomics signature was built with the logistic regression model of the training cohort, and the radiomics signature performance was evaluated using the validation cohort and an independent testing data set.
RESULTS: The radiomics signature built on 9 selected features showed good discrimination in both the training and validation cohorts for T2-FLAIR. The radiomics signature of T2-FLAIR yielded an AUC of 0.987, a classification accuracy of 0.991, sensitivity of 1.000, and specificity of 0.980 in the validation cohort. The AUC was 0.871 in the independent testing data set. The AUCs of our radiomics signature to differentiate exon 19 and exon 21 mutations were 0.529, 0.580, 0.645, and 0.406 for T1-CE, T2-FLAIR, T2WI, and DWI, respectively.
CONCLUSIONS: We developed a T2-FLAIR radiomics signature that can be used as a noninvasive auxiliary tool for predicting EGFR mutation status in lung adenocarcinoma, which is helpful to guide therapeutic strategies.
KEY POINTS: • MR-based radiomics signature of brain metastasis may help predict EGFR mutation status in lung adenocarcinoma, especially using T2-FLAIR. • Nine radiomics features extracted from T2-FLAIR sequence strongly correlate with EGFR mutation status. • Radiomics features reflect tumor heterogeneity through potential changes in tissue morphology caused by EGFR mutation.
引用
- Wang G, Wang B, Wang Z, et al. Radiomics signature of brain metastasis: prediction of EGFR mutation status. Eur Radiol. 2021. PMID: 33439315. doi:10.1007/s00330-020-07614-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。